Paracetamol: are therapeutic doses entirely safe?

Lancet

Volumn 368, Issue 9554, 2006, Pages 2195-2196

  Jalan, Rajiv ^a   Williams, Roger ^a   Bernuau, Jacques ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; HYDROCODONE; OPIATE; PARACETAMOL; PLACEBO;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG OVERDOSE; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; INGESTION; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALNUTRITION; NEPHROTOXICITY; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VIRUS HEPATITIS;

EID: 33845629820     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69874-7     Document Type: Note

References (13)

1. Moynihan R. FDA fails to reduce accessibility of paracetamol despite 450 deaths a year. BMJ 325 (2002) 678
2. Ostapowicz G., Fontana R., Schiodt F., and for the US Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137 (2002) 945-954
3. O'Grady J., Schalm S., and Williams R. Acute liver failure: redefining the syndromes. Lancet 342 (1993) 273-275
4. Larson A., Polson J., Fontana R., and for the Acute Liver Failure Study Group. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 42 (2005) 1364-1372
5. US Food and Drug Administration. CDER 2002 meeting documents (Aug 17, 2006). http://www.fda.gov/ohrms/dockets/ac/cder02.htm#NonprescriptionDrugs (accessed Dec 18, 2006).
6. Watkins P., Kaplowitz N., Slattery J., et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 296 (2006) 87-93
7. Kwan D., Bartle W., and Walker S. Abnormal serum transaminases following therapeutic doses of acetaminophen in the absence of known risk factors. Dig Dis Sci 40 (1995) 1951-1955
8. Critchley J., Nimmo G., Gregson C., Woolhouse N., and Prescott L. Inter-subject and ethnic differences in paracetamol metabolism. Br J Clin Pharmacol 22 (1986) 649-657
9. Yin O., Tomlinson B., Chow A., and Chow M. Pharmacokinetics of acetaminophen in Hong Kong Chinese subjects. Int J Pharm 222 (2001) 305-308
10. Yaghi C., Honein K., Boujaoude J., Slim R., Moucari R., and Sayegh R. Influence of acetaminophen at therapeutic doses on surrogate markers of severity of acute viral hepatitis. Gastroenterol Clin Biol 30 (2006) 763-768
11. Polson J., James L., Davern T., et al. Acetaminophen as a co-factor in acute liver failure due to viral hepatitis determined by measurement of acetaminophen-protein adducts. Gastroenterology 130 suppl (2006) A-772 (abstr).
12. Bernuau J., Cazals-Hayem D., Francoz C., et al. Chronic and acute co-factors of acute liver disease in patients on anti-tuberculous treatment: high prevalence of recent ingestion of paracetamol in uninformed patients: a prospective study. Hepatology 40 (2004) 499 (abstr).
13. Prescott L. Paracetamol overdosage: pharmacological considerations and clinical management. Drugs 25 (1983) 290-314